| dc.description.abstract | The sickness of stomach ulcers is quite typical. Helicobacter pylori infection will result
in serious consequences, especially cancer, if not quickly and efficiently treated. Since it
was discovered and first published in 1983 by Warren J.R. and Marshall B.J., Helicobacter pylori has continued to draw the attention of scientists from all around the
globe. As antibiotic resistance among Helicobacter pylori (H pylori) spreads globally, the effectiveness of current treatment methods for eradication is decreasing. The
determination of Helicobacter pylori susceptibility to antibiotics to monitor the tendency
of Helicobacter pylori to antibiotic resistance serves as a basis for selecting appropriate
regimens and optimizing the effectiveness of Helicobacter pylori eradication treatment. Biopsy samples from stomach ulcers were obtained for the purposes of HP isolation, culture, and investigation of the HP susceptibility to amoxicillin, clarithromycin, levofloxacin, tetracycline, metronidazole. Also, the impact of multiple drug resistance, age, gender on drug resistance rate were studied. In total, 769 gastric ulcers biopsy specimens were collected from January/2022 to
October/2022. 401 HP clinical strains were successfully isolated and cultured. The
resistance rates of tetracycline, metronidazole, amoxicillin, levofloxacin, clarithromycin
were 1%, 10.72%, 16.96%, 62.84%, and 96.26%, respectively. The total rate of dual
resistance was 55.36%. Triple resistance was 13.72%. HP resistance to conventional antibiotics is a serious issue right now. The most effective
antibiotic for eliminating HP is tetracycline, which is followed by metronidazole. Yet, if
HP cannot be completely eradicated, resistance rates may increase. To increase the
primary eradication rate, it is important to strengthen the standardized HP diagnosis and
treatment. | en_US |
